Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GSK GSK	$40.50 -0.9%	$38.22	$31.72 ▼ $44.67	$83.00B	0.52	4.88 million shs	4.65 million shs
ONC Beigene	$264.42 -1.9%	$242.48	$141.31 ▼ $287.88	$28.95B	0.3	449,956 shs	326,595 shs
SNY Sanofi	$49.41 -0.5%	$51.48	$45.80 ▼ $60.12	$121.18B	0.5	2.38 million shs	1.95 million shs
TAK Takeda Pharmaceutical	$15.07 -0.9%	$14.73	$12.58 ▼ $15.43	$47.94B	0.23	1.96 million shs	1.89 million shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GSK GSK	0.00%	-0.98%	+8.46%	+1.28%	+0.41%
ONC Beigene	0.00%	+5.38%	+18.06%	+1.72%	+26,962,999,900.00%
SNY Sanofi	0.00%	-1.59%	-3.89%	-15.70%	+7.39%
TAK Takeda Pharmaceutical	0.00%	+1.57%	+7.76%	+0.16%	+16.03%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GSK GSK	1.7426 of 5 stars	1.1	4.0	2.5	2.1	0.0	1.9
ONC Beigene	1.4775 of 5 stars	2.5	0.0	0.0	2.8	1.7	0.6
SNY Sanofi	3.4265 of 5 stars	2.6	3.0	2.5	2.2	0.0	3.1
TAK Takeda Pharmaceutical	2.0206 of 5 stars	0.0	3.0	1.7	2.0	0.0	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GSK GSK	2.27	Hold	$37.38	-7.71% Downside
ONC Beigene	3.00	Buy	$319.00	20.64% Upside
SNY Sanofi	3.13	Buy	$61.50	24.47% Upside
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest ONC, SNY, GSK, and TAK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/3/2025	SNY Sanofi	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/3/2025	GSK GSK	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
6/2/2025	SNY Sanofi	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$56.00
5/8/2025	ONC Beigene	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$312.00 ➝ $311.00
5/8/2025	ONC Beigene	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$348.00 ➝ $350.00
4/28/2025	GSK GSK	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
4/28/2025	ONC Beigene	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$312.00 ➝ $312.00
4/28/2025	SNY Sanofi	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/24/2025	ONC Beigene	TD Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$334.00 ➝ $334.00
4/21/2025	ONC Beigene	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$311.00 ➝ $317.00
4/16/2025	ONC Beigene	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GSK GSK	$31.53B	2.63	$6.41 per share	6.32	$8.07 per share	5.02
ONC Beigene	$4.18B	6.93	N/A	N/A	$37.10 per share	7.13
SNY Sanofi	$45.17B	2.68	$4.86 per share	10.16	$33.20 per share	1.49
TAK Takeda Pharmaceutical	$4.58T	0.01	$3.53 per share	4.27	$15.39 per share	0.98

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GSK GSK	$3.29B	$1.94	25.47	8.71	1.12	8.13%	48.59%	11.11%	7/30/2025 (Estimated)
ONC Beigene	-$881.71M	-$3.72	N/A	372.42	7.73	-25.94%	-25.12%	-14.95%	N/A
SNY Sanofi	$6.02B	$2.80	19.84	10.40	1.01	12.77%	25.61%	14.72%	7/24/2025 (Estimated)
TAK Takeda Pharmaceutical	$994.06M	$0.22	37.66	9.13	0.24	4.53%	9.39%	4.53%	7/30/2025 (Estimated)

Latest ONC, SNY, GSK, and TAK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q4 2025	TAK Takeda Pharmaceutical	$0.24	$0.16	-$0.08	-$0.21	$8.02 billion	$7.34 billion
5/7/2025	Q1 2025	ONC Beigene	-$0.71	$1.22	+$1.93	$0.01	$1.12 billion	$1.12 billion
4/30/2025	Q1 2025	GSK GSK	$1.08	$1.13	+$0.05	$1.00	$7.52 billion	$10.06 billion
4/24/2025	Q1 2025	SNY Sanofi	$0.90	$0.94	+$0.04	$0.80	$9.79 billion	$10.41 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GSK GSK	$1.68	4.15%	N/A	86.60%	N/A
ONC Beigene	N/A	N/A	N/A	N/A	N/A
SNY Sanofi	$1.59	3.22%	N/A	56.79%	N/A
TAK Takeda Pharmaceutical	$0.26	1.73%	N/A	118.18%	N/A

Latest ONC, SNY, GSK, and TAK Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/2/2025	GSK GSK	quarterly	$0.4216	4.1%	5/16/2025	5/16/2025	7/10/2025
4/15/2025	SNY Sanofi	annual	$2.0369	3.1%	5/9/2025	5/9/2025	6/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GSK GSK	1.12	0.78	0.52
ONC Beigene	0.05	1.93	1.72
SNY Sanofi	0.15	1.46	1.14
TAK Takeda Pharmaceutical	0.63	1.31	0.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GSK GSK	15.74%
ONC Beigene	48.55%
SNY Sanofi	14.04%
TAK Takeda Pharmaceutical	9.17%

Insider Ownership

Company	Insider Ownership
GSK GSK	10.00%
ONC Beigene	6.62%
SNY Sanofi	1.00%
TAK Takeda Pharmaceutical	0.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GSK GSK	90,100	2.05 billion	1.87 billion	Optionable
ONC Beigene	9,000	109.49 million	90.59 million	N/A
SNY Sanofi	91,600	2.45 billion	2.51 billion	Optionable
TAK Takeda Pharmaceutical	47,300	3.18 billion	3.18 billion	Optionable

ONC, SNY, GSK, and TAK Headlines

Recent News About These Companies

GAMMA Investing LLC Has $1.56 Million Stock Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

June 15 at 3:39 AM | marketbeat.com

Sun Pharma announce major leadership shake-up, names Kirti Ganorkar as MD, Shanghvi steps into executive Chairman Role

June 14 at 1:19 AM | moneycontrol.com

Sun Pharma names Kirti Ganorkar as new managing director, Dilip Shanghvi to continue as chairman

June 13 at 3:16 PM | msn.com

Wealth Enhancement Advisory Services LLC Lowers Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

June 9, 2025 | marketbeat.com

Clean Yield Group Lowers Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

June 8, 2025 | marketbeat.com

Takeda CEO Christophe Weber faces opposition to board reelection

June 7, 2025 | asia.nikkei.com

Itochu working to support overseas pharma firms to fill Japan's drug gaps

June 4, 2025 | japantimes.co.jp

Takeda Reports Adcetris Combo Approved by EC for Hodgkin Lymphoma

June 4, 2025 | msn.com

Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Bought by NBC Securities Inc.

June 4, 2025 | marketbeat.com

Takeda Pharmaceutical Company Limited (NYSE:TAK) Short Interest Up 33.3% in May

June 3, 2025 | marketbeat.com

Medicamen Biotech rallies after securing USFDA approval for Bortezomib injection

June 3, 2025 | business-standard.com

Rusfertide reduces blood draws, maintains hematocrit, eases symptoms in polycythemia vera

June 2, 2025 | healio.com

ASCO: Takeda and Protagonist release positive Phase III VERIFY study of rusfertide in polycythemia vera

June 2, 2025 | thepharmaletter.com

Legacy Wealth Asset Management LLC Buys 44,635 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

June 2, 2025 | marketbeat.com

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

June 1, 2025 | businesswire.com

Versant Capital Management Inc Purchases 23,166 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

June 1, 2025 | marketbeat.com

At the WBUR Festival, exploring the good and bad scenarios for Massachusetts’ future

May 31, 2025 | msn.com

Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Sold by Summit Global Investments

May 31, 2025 | marketbeat.com

Toronto Dominion Bank Takes $6.76 Million Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 31, 2025 | marketbeat.com

Two Sigma Advisers LP Increases Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

May 30, 2025 | marketbeat.com

Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Sold by Bank of America Corp DE

May 30, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Beaten-Down Stocks Trading 50% Below Their 52-Week Highs
By Leo Miller | May 27, 2025
View 3 Beaten-Down Stocks Trading 50% Below Their 52-Week Highs
Turbulence for Joby Shares: What's Behind the Recent Dip?
By Jeffrey Neal Johnson | May 22, 2025
View Turbulence for Joby Shares: What's Behind the Recent Dip?
RKLB Breakout Fails Near Highs: Should Investors Be Concerned?
By Ryan Hasson | June 11, 2025
View RKLB Breakout Fails Near Highs: Should Investors Be Concerned?
Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern
By Leo Miller | June 2, 2025
View Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern
Palantir Soars on Government Deals as Valuation Debate Lingers
By Chris Markoch | June 3, 2025
View Palantir Soars on Government Deals as Valuation Debate Lingers

ONC, SNY, GSK, and TAK Company Descriptions

GSK NYSE:GSK

$40.50 -0.36 (-0.89%)

Closing price 03:59 PM Eastern

Extended Trading

$40.55 +0.05 (+0.13%)

As of 05:52 PM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Beigene NASDAQ:ONC

$264.42 -5.21 (-1.93%)

As of 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Sanofi NASDAQ:SNY

$49.41 -0.26 (-0.52%)

Closing price 04:00 PM Eastern

Extended Trading

$49.50 +0.09 (+0.18%)

As of 07:53 PM Eastern

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Takeda Pharmaceutical NYSE:TAK

$15.06 -0.14 (-0.89%)

Closing price 03:59 PM Eastern

Extended Trading

$15.06 0.00 (0.00%)

As of 04:10 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time